Merck Group’s Bio-Based Solvent For Sustainable Laboratories

The pharmaceutical and life sciences industry is continuously being reshaped by sustainability goals alongside strict manufacturing and analytical performance requirements. 

Advances in green chemistry and bio-based inputs are now influencing how essential laboratory materials are produced. 

One of the latest developments in this space is Merck Group’s introduction of a bio-based solvent portfolio for high-performance liquid chromatography (HPLC). 

This innovation reflects a broader shift toward reducing environmental impact without compromising precision in healthcare and pharmaceutical workflows.

Sustainable bio-based solvents

Merck Group has introduced the first bio-based solvent portfolio specifically designed for HPLC, marking a significant step in sustainable laboratory manufacturing. 

The solvents are produced using renewable feedstocks and are engineered as drop-in replacements for widely used materials such as acetonitrile, methanol and ethanol. 

According to the company, the new portfolio achieves an average reduction of 25.9% in CO₂e compared to conventional fossil-fuel-based chromatography solvents, while maintaining the high-performance standards required in analytical testing.

A key feature of this development is its compatibility with existing HPLC and liquid chromatography mass spectrometry systems, allowing laboratories to adopt the solvents without the need for method redevelopment. 

This is particularly important in regulated pharmaceutical environments, where analytical consistency and validation requirements can make process changes complex and time-consuming. 

“Our new bio-based HPLC solvents represent the next generation of high-performance liquid chromatography,” says Karen Madden, Chief Technology Officer, Life Science business of Merck.

“Customers are looking for solutions that help reduce environmental impact without compromising performance quality. 

“This innovative portfolio aims to deliver the precision, quality and reliability expected in HPLC and is designed to integrate seamlessly into existing methods.”

The innovation also supports applications across drug development, manufacturing quality control, environmental analysis and diagnostics, where chromatography plays a central role in ensuring accurate molecular separation and measurement.

Manufacturing implications for life sciences

Merck’s approach demonstrates how pharmaceutical supply chains are integrating greener raw materials while maintaining industrial-scale reliability. 

By using proprietary production processes and renewable inputs, the company is aligning laboratory consumables with broader decarbonisation strategies across the life sciences sector. 

This shift also reflects increasing demand from pharmaceutical manufacturers and research institutions for products that reduce environmental footprint without disrupting established analytical workflows. 

As a result, bio-based chromatography solvents represent an important intersection between performance-driven science and sustainable industrial manufacturing.

How is chromatography applied in healthcare? 

Chromatography can play a critical role in healthcare and medical device manufacturing through its use in purification, separation and extraction processes, particularly in pharmaceutical-grade resin systems, as highlighted by Ecolab. 

These resins are used in medical technologies such as extracorporeal blood purification systems in dialysis and nanodialysis machines, enzyme-based glucose sensors and purification processes for nutrition products including infant formulas. 

They also support therapeutic applications addressing conditions such as kidney and liver failure, diabetes, cystic fibrosis and immunodeficiencies.

Ecolab notes that these materials must meet strict regulatory requirements and standards governing extractables, leachables and toxicological safety in medical devices. 

This regulatory and manufacturing structure ensures that chromatography-based materials used in healthcare maintain both patient safety and global quality consistency across diagnostic and therapeutic applications.